Navigation Links
ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
Date:2/29/2008

tive new medicines to their fullest potential, said Elliott Sigal, M.D., Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb. Expanding the clinical use of an important therapy such as ABILIFY gives pediatric patients with Bipolar I Disorder and their caregivers a new treatment option in their fight against this serious disease.

Clinical Trial Design and Findings

These findings are from a four-week, multicenter, randomized, double-blind, placebo-controlled study, which evaluated the efficacy and safety of ABILIFY in 296 pediatric patients (10 to 17 years old) with a DSM-IV diagnosis of Bipolar I Disorder, manic or mixed episodes, with or without psychotic features. Diagnosis was made by a trained child and adolescent psychiatrist and confirmed by a separate diagnostic interview. This study was conducted on an outpatient basis with the possibility of inpatient hospitalization, as needed. This clinical trial was sponsored by Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, NJ) with enrollment at 54 U.S. centers.

After a screening period of up to four weeks, pediatric patients (10 to 17 years old) who scored greater than or equal to 20 on the Y-MRS* were randomly assigned to receive one of two fixed doses of ABILIFY [10 mg/day (n=98) or 30 mg/day (n=99)] or placebo (n=99). ABILIFY was initiated at a starting dose of 2 mg/day and titrated to the target dose of 10 mg/day or 30 mg/day.

The primary efficacy endpoint was the mean change in the Y-MRS Total Score from baseline to Week 4. Safety evaluations included incidence of adverse reactions, discontinuation due to adverse reactions, laboratory measures and body weight.

For the primary endpoint, both doses of ABILIFY demonstrated statistically significant improvement in symptoms when compared to placebo (p-value less t
'/>"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Otsuka America Pharmaceutical, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. US FDA approves ABILIFY for adolescent patients with schizophrenia
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
3. ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
4. FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
5. $52.5 Million Settlement Against Sepracor Inc. Approved
6. FDA Cracks Down on Unapproved Cough Medicines
7. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
8. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
9. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
10. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
11. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
(Date:7/13/2014)... 13, 2014 Celebrity fitness trainer and ... a promotional partnership with Aqua Health Labs for their ... EPA supplement . The collaboration was recently announced live ... fitness trainer , actor, model, and a two time ... A-List celebrities, he has prepared stars including Demi Moore, ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... The Chicken Egg Production industry ... buoyed by stable demand for industry products as well ... a relatively affordable staple for most families across Canada; ... in line with the size of the population,” according ... new specialty egg products with enriched qualities, such as ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... solutions to support and enhance healthcare delivery.CHICAGO, March 31 ... by 35 years of healthcare IT experience, Siemens Healthcare ... ) will unveil its latest portfolio of healthcare ... Systems Society (HIMSS) 2009 Annual Conference and Exhibition in ...
... 31 CareFusion Corporation, the company that is expected ... clinical and medical products businesses, today filed a Form ... (SEC) that contains detailed information about the company as ... Cardinal Health,s plan to spin off at least 80 ...
... the 13 most prevalent serotypes associated with pneumococcal disease ... a division of Wyeth (NYSE: WYE ), ... Application (BLA) to the U.S. Food and Drug Administration ... CRM(197) Protein). Last year, the FDA granted Prevnar ...
... Difficult-to-remember generic drug names. Unregulated continuing medical ... two of the strategies used by some in ... of doctors, according to a Georgetown University Medical ... aimed at increasing physician access to unbiased information ...
... Tech Industry Veteran Will Focus on Broader Product ... 31 DecisionView, Inc., the leading provider of ... today announced that its Board of Directors has ... Chairman, President and CEO of DecisionView, effective immediately. ...
... Age 40 to 79 Have Experienced a Life ... a Spouse or Major Illness or DisabilityWomen Significantly ... EmotionallyAARP Financial Inc. President Says Understanding Emotions, Getting ... Finances in a Life CrisisAARP Financial Inc. Offers ...
Cached Medicine News:Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 2Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 3Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 4Health News:Answers for Life: Siemens' Latest Cutting-Edge Health IT Technology Takes Center Stage at HIMSS 2009 5Health News:CareFusion Corporation Files Form 10 Registration Statement 2Health News:CareFusion Corporation Files Form 10 Registration Statement 3Health News:CareFusion Corporation Files Form 10 Registration Statement 4Health News:CareFusion Corporation Files Form 10 Registration Statement 5Health News:CareFusion Corporation Files Form 10 Registration Statement 6Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 2Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 3Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 4Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 5Health News:Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers 6Health News:GUMC researcher creates first Web-interactive CME course for physicians on pharmaceutical marketing 2Health News:GUMC researcher creates first Web-interactive CME course for physicians on pharmaceutical marketing 3Health News:DecisionView Board of Directors Appoints James P. Scullion as CEO and President 2Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 2Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 3Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 4Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 5Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 6Health News:AARP Financial Inc. Survey Finds: Vast Majority of Families Struggle With Financial Implications of a Life Crisis 7
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: